177 related articles for article (PubMed ID: 14508854)
1. Translational research in lung cancer.
Chen Y; Okunieff P; Ahrendt SA
Semin Surg Oncol; 2003; 21(3):205-19. PubMed ID: 14508854
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.
Dacic S
Expert Rev Mol Diagn; 2007 Jan; 7(1):77-86. PubMed ID: 17187486
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer: future directions.
Lam WK; Watkins DN
Respirology; 2007 Jul; 12(4):471-7. PubMed ID: 17587411
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients.
Novakova-Jiresova A; Van Gameren MM; Coppes RP; Kampinga HH; Groen HJ
Radiother Oncol; 2004 May; 71(2):183-9. PubMed ID: 15110452
[TBL] [Abstract][Full Text] [Related]
5. The biology of non-small-cell lung cancer: identifying new targets for rational therapy.
Rosell R; Felip E; Garcia-Campelo R; Balaña C
Lung Cancer; 2004 Nov; 46(2):135-48. PubMed ID: 15474661
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of non-small-cell lung cancer.
Lacroix L; Commo F; Soria JC
Expert Rev Mol Diagn; 2008 Mar; 8(2):167-78. PubMed ID: 18366303
[TBL] [Abstract][Full Text] [Related]
7. Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.
Tomaszek SC; Huebner M; Wigle DA
Expert Rev Respir Med; 2010 Aug; 4(4):499-508. PubMed ID: 20658911
[TBL] [Abstract][Full Text] [Related]
8. Molecular biologic staging of lung cancer.
D'Amico TA
Ann Thorac Surg; 2008 Feb; 85(2):S737-42. PubMed ID: 18222207
[TBL] [Abstract][Full Text] [Related]
9. The role of targeted therapy in non-small cell lung cancer.
Maione P; Rossi A; Airoma G; Ferrara C; Castaldo V; Gridelli C
Crit Rev Oncol Hematol; 2004 Jul; 51(1):29-44. PubMed ID: 15207252
[TBL] [Abstract][Full Text] [Related]
10. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Mehta V
Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetic tumor markers in non-small cell lung cancer.
Oyama T; Osaki T; Baba T; Nagata Y; Mizukami M; So T; Nakata S; Ichiki Y; Uramoto H; Sugaya M; Yoshimatsu T; Morita M; Hanagiri T; Sugio K; Kawamoto T; Yasumoto K
Anticancer Res; 2005; 25(2B):1193-6. PubMed ID: 15865065
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
[TBL] [Abstract][Full Text] [Related]
13. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
[TBL] [Abstract][Full Text] [Related]
14. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
15. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer.
De Jaeger K; Seppenwoolde Y; Kampinga HH; Boersma LJ; Belderbos JS; Lebesque JV
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1378-87. PubMed ID: 15050313
[TBL] [Abstract][Full Text] [Related]
16. Complex and controversial issues in locally advanced non-small cell lung carcinoma.
Machtay M; Jeremic B
Semin Surg Oncol; 2003; 21(2):128-37. PubMed ID: 14508863
[TBL] [Abstract][Full Text] [Related]
17. Targeting novel and established therapies for non-small cell lung cancer.
Spicer J; Chowdhury S; Harper P
Cancer Lett; 2007 May; 250(1):9-16. PubMed ID: 17030089
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with human small aggressive non small cell lung cancer.
Tammemagi CM; Freedman MT; Church TR; Oken MM; Hocking WG; Kvale PA; Hu P; Riley TL; Ragard LR; Prorok PC; Berg CD
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2082-9. PubMed ID: 17932357
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
[TBL] [Abstract][Full Text] [Related]
20. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.
Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG
Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
